Furthermore, tumor molecular heterogeneity between our patients and those in prior studies may also contribute to the incidence difference, particularly for molecules that can modulate tumor epileptogenicity through mechanisms independent of IDH status, for instance, ion channel dysfunction [20, 21]. Here, IDH1 is linked to neoplasm.